Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Oramed Pharmaceuticals Inc. (ORMP)

8.41   0.52 (6.59%) 11-25 13:00
Open: 7.91 Pre. Close: 7.89
High: 8.49 Low: 7.9
Volume: 153,724 Market Cap: 329(M)

Technical analysis

as of: 2022-11-25 1:59:22 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 11.34     One year: 13.24
Support: Support1: 7.46    Support2: 6.07
Resistance: Resistance1: 9.71    Resistance2: 11.34
Pivot: 7.52
Moving Average: MA(5): 7.87     MA(20): 7.35
MA(100): 7.77     MA(250): 8.3
MACD: MACD(12,26): 0.3     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 50.8     %D(3): 46.8
RSI: RSI(14): 61.4
52-week: High: 17.63  Low: 3.58
Average Vol(K): 3-Month: 270 (K)  10-Days: 403 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ORMP ] has closed below upper band by 21.7%. Bollinger Bands are 25% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.98 - 8.04 8.04 - 8.08
Low: 7.36 - 7.42 7.42 - 7.46
Close: 7.81 - 7.9 7.9 - 7.98

Company Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Headline News

Mon, 14 Nov 2022
Oramed Pharma (ORMP) Enters Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea - StreetInsider.com

Thu, 10 Nov 2022
Oramed Reports Third Quarter 2022 Financial Results USA - English - USA - English - PR Newswire

Thu, 10 Nov 2022
Oramed: Q3 Earnings Snapshot - San Antonio Express-News

Thu, 10 Nov 2022
Oramed Pharmaceuticals GAAP EPS of -$0.18, revenue of $2.02M (NASDAQ:ORMP) - Seeking Alpha

Wed, 19 Oct 2022
Where Does Oramed Pharmaceuticals, Inc. (ORMP) Stock Fall in the Biotechnology Field After It Is Higher By 7.87% This Week? - InvestorsObserver

Wed, 12 Oct 2022
Despite currently being unprofitable, Oramed Pharmaceuticals (NASDAQ:ORMP) has delivered a 94% return to shareholders over 3 years - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 39 (M)
% Held by Insiders 3.743e+007 (%)
% Held by Institutions 5.2 (%)
Shares Short 3,100 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.927e+007
EPS Est Next Qtl -0.28
EPS Est This Year -0.78
EPS Est Next Year -1.25
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 817.7
Return on Equity (ttm) 0
Qtrly Rev. Growth 2.71e+006
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 1.1886e+006
Qtrly Earnings Growth -1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -39 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 4.87

Stock Dividends

Dividend 0
Forward Dividend 3.02e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.